UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 281

Sortiert nach

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

Nature medicine, 2010-04, Vol.16 (4), p.460-465

2010

Volltextzugriff (PDF)

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Clinical infectious diseases, 2015-08, Vol.61 (3), p.403-408

2015

Volltextzugriff (PDF)

Commentary: Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens

Frontiers in immunology, 2022-04, Vol.13, p.904689-904689

2022

Volltextzugriff (PDF)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy

PloS one, 2016-05, Vol.11 (5), p.e0155406

2016

Volltextzugriff (PDF)

Reassessing oral lead-in for injectable long-acting HIV therapy

The lancet HIV, 2021-11, Vol.8 (11), p.e660-e661

2021

Volltextzugriff (PDF)

High-level dolutegravir resistance selection on dolutegravir/lamivudine

Clinical infectious diseases, 2024-03

2024

Volltextzugriff (PDF)

Clinical Implications of Genotypic Resistance to the Newer Antiretroviral Drugs in HIV-1–Infected Patients with Virological Failure

Clinical infectious diseases, 2010-03, Vol.50 (6), p.872-881

2010

Volltextzugriff (PDF)

Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors

AIDS reviews, 2019-01, Vol.21 (1), p.4-10

2019

Volltextzugriff (PDF)

Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study

Frontiers in immunology, 2024-05, Vol.15, p.1394644

2024

Volltextzugriff (PDF)

Deep molecular characterization of HIV-1 dynamics under suppressive HAART

PLoS pathogens, 2011-10, Vol.7 (10), p.e1002314

2011

Volltextzugriff (PDF)

IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors

Frontiers in immunology, 2023-10, Vol.14, p.1257725-1257725

2023

Volltextzugriff (PDF)

Prevention of Anal Cancer

The New England journal of medicine, 2022-08, Vol.387 (7), p.666

2022

Volltextzugriff (PDF)

Normalization of circulating plasma levels of miRNAs in HIV-1/HCV co-infected patients following direct-acting antiviral–induced sustained virologic response

Heliyon, 2023-01, Vol.9 (1), p.e12686-e12686, Article e12686

2023

Volltextzugriff (PDF)

Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study

EClinicalMedicine, 2022-10, Vol.52, p.101600-101600, Article 101600

2022

Volltextzugriff (PDF)

Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals

PloS one, 2014-12, Vol.9 (12), p.e114142-e114142

2014

Volltextzugriff (PDF)

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

AIDS (London), 2013-01, Vol.27 (1), p.81-85

2013

Volltextzugriff (PDF)

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

The Lancet (British edition), 2018-03, Vol.391 (10123), p.839-849

2018

Volltextzugriff (PDF)

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

The New England journal of medicine, 2015-08, Vol.373 (9), p.795-807

2015

Volltextzugriff (PDF)

EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment

PloS one, 2016-02, Vol.11 (2), p.e0149007-e0149007

2016

Volltextzugriff (PDF)

Male genitourinary schistosomiasis-related symptoms among long-term Western African migrants in Spain: a prospective population-based screening study

Infectious diseases of poverty, 2024-03, Vol.13 (1), p.23-23, Article 23

2024

Volltextzugriff (PDF)

Corrigendum: Feasibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen self-testing in school and summer camp attendees

Frontiers in pediatrics, 2023, Vol.11, p.1353806-1353806

2023

Volltextzugriff (PDF)

Comparative Analysis of Primary and Monovalent Booster SARS-CoV-2 Vaccination Coverage in Adults with and without HIV in Catalonia, Spain

Vaccines (Basel), 2023-12, Vol.12 (1), p.44

2023

Volltextzugriff (PDF)

Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia

PloS one, 2015-06, Vol.10 (6), p.e0128131

2015

Volltextzugriff (PDF)

Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019

Clinical infectious diseases, 2021-10, Vol.73 (7), p.e1964-e1972

2021

Volltextzugriff (PDF)

Time to get serious with HIV-1 resistance in sub-Saharan Africa

The Lancet infectious diseases, 2017-03, Vol.17 (3), p.241-243

Llibre, Josep M

2017

Volltextzugriff (PDF)

1 – 25 von 281

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(251)
Mit Volltextzugriff
(243)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Commentary: Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy

Reassessing oral lead-in for injectable long-acting HIV therapy

High-level dolutegravir resistance selection on dolutegravir/lamivudine

Clinical Implications of Genotypic Resistance to the Newer Antiretroviral Drugs in HIV-1–Infected Patients with Virological Failure

Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors

Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study

Deep molecular characterization of HIV-1 dynamics under suppressive HAART

IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors

Prevention of Anal Cancer

Normalization of circulating plasma levels of miRNAs in HIV-1/HCV co-infected patients following direct-acting antiviral–induced sustained virologic response

Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study

Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment

Male genitourinary schistosomiasis-related symptoms among long-term Western African migrants in Spain: a prospective population-based screening study

Corrigendum: Feasibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen self-testing in school and summer camp attendees

Comparative Analysis of Primary and Monovalent Booster SARS-CoV-2 Vaccination Coverage in Adults with and without HIV in Catalonia, Spain

Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia

Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019

Time to get serious with HIV-1 resistance in sub-Saharan Africa

Suchergebnisse filtern